Winter in a cold climate can add challenges when caregiving for someone with dementia, columnist Ray Burow writes.

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease. The company ...

Alzheimer’s disease is characterized by the protein plaques and tangles that are thought to be responsible for cell death and tissue loss in the brain. Tangles are twisted fibers of a protein called ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

There is no cure for Alzheimer’s Disease (AD), but some medications may help reduce the symptoms or slow progression of the disease. As AD progresses, brain cells die and the connections between them ...

There is a rapid growth in the number of people living with Alzheimer’s disease, and only around one in four people with the disease get diagnosed. It is estimated that there are approximately 44 ...

Alzheimer’s disease is a progressive neurodegenerative disorder that is characterized by declining mental abilities that affect memory, cognitive function, and personality. It is the most common cause ...

Alzheimer’s disease (AD) is associated with a gradual decline in memory and mental ability, due to the accumulation and spread of damage in the brain. It is an irreversible condition, with symptoms ...

Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia. It most often emerges during a person’s mid-60s or older, although early-onset varieties exist.